Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Theralase Technologies Inc. TLTFF


Primary Symbol: V.TLT Alternate Symbol(s):  V.TLT.W

Theralase Technologies Inc is a clinical stage pharmaceutical company. It is dedicated to the research and development of light activated Photo Dynamic Compounds, their associated drug formulations and technology platforms intended to safely and effectively; treat various cancers, bacteria and viruses. The Cool Laser Technology division designs, develops, manufactures and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, primarily in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (OTCQB:TLTFF)

Fundamentals Snapshot (OTCQB:TLTFF)

Bullboard Posts (TSXV:TLT)

RE:RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA

TLT once mentioned 100K$US, just a bit below Keytruda cost.  Enough profitability, while being just below KEYTRUDA cost, but with...
ScienceFirst - 1 minute ago

RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA

I believe in previous corporate presentations Theralase has estimated a cost of 50K to 150K.
Eoganacht - 3 minutes ago

RE:Research Capital’s 0.80$ target is amusing

It is amusing.  However, fully diluted there's currently over like 320 million shares outstanding.  I read some on this...
2b7f6fab - 3 minutes ago

RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA

Rumpl3, You consider $20K for 2 treatments or $40K total "steep"? Compare it to the current Standard of Care. $15K each every 3...
skys1 - 18 minutes ago

RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA

I think ultimately the market will get this one right. Remember, there are many pharmas and biotechs who will want something like this...
Rumpl3StiltSkin - 31 minutes ago

RE:2 weeks: It’s all it took for Merck to get AA

This very complete paper of March 2021 clearly shows that the only 2 FDA approved BCG-Unresponsive drugs are not convincing. ...
ScienceFirst - 1 hour ago